AT
Actinium Pharmaceuticals, Inc.
ATNM · AMEX
$1.21 +1.26% (+$0.02)
1M +10.91%
Market Cap $37.6M
P/E Ratio 3.33x
Div. Yield -
ROE 83.42%
Bulios Fair Price
$1.75
45.2% upside
Current Price
$1.21
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ATNM is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/S 1.07x
P/E 3.33x
P/B 1.24x
Growth
0 /100
Declining Book val. growth 50.97%
Rev. growth 55.63%
FCF growth N/A
Profitability
70 /100
Strong Op. margin 27.23%
Gross margin 101.13%
FCF margin 66.25%
Quality
96 /100
Excellent ROA 28.16%
ROIC 30.20%
Asset turnover 0.87x
Debt
100 /100
Low Net debt/EBITDA -2.88x
Debt/Equity 0.04x
Current ratio 4.08x
Stability
27 /100
Unstable Profitable years 0
Beta 0.02x
EPS volatility 33.34%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ATNM
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sandesh C. Seth
Employees
27
Headquarters
New York City
Upcoming events
13 NOV
Earnings
Upcoming earnings report